| Kaplan Meier Estimates | ||||
---|---|---|---|---|---|
5-Year Absence of Hepatocellular Carcinoma (%) | Â | After Propensity Score Matching | |||
 | Metformin | Metformin + SGLT2-i | P | HR (95%CI) | |
All |  | 93.75 | 98.61 | 0.017 | 0.43 (0.21–0.88) |
Subgroup a | Â | Â | Â | Â | - |
 Men |  | 86.91 | 99.64 | 0.051 | 0.24 (0.05–1.14) |
 Women |  | 85.02 | 97.72 | 0.106 | 0.52 (0.23–1.16) |
 White |  | 92.71 | 98.18 | 0.029 | 0.44 (0.21–0.93) |
 Non-White |  | 96.87 | 99.49 | 0.100 | 0.2 (0.02–1.69) |
 Hispanic |  | 95.54 | 99.17 | 0.385 | 0.38 (0.04–3.7) |
 Non-Hispanic |  | 93.32 | 98.18 | 0.037 | 0.46 (0.22–0.97) |
 Age 39–59 |  | 95.21 | 99.44 | 0.134 | 0.31 (0.06–1.56) |
 Age 60–80 |  | 97.18 | 98.64 | 0.051 | 0.4 (0.16–1.03) |
MASH b |  | 93.61 | 98.72 | 0.120 | 0.08 (0.01–0.62) |